UK launches £100m AI Biosecurity Lab backed by OpenAI and Anthropic credits

The British government has announced the AI Biosecurity Lab, which it describes as the first organisation anywhere devoted to the intersection of artificial intelligence and biological risk. The notice went up on GOV.UK just after midnight on 24 October 2026 and presents the lab as the centrepiece of a wider National AI Biosecurity Initiative. It is to be set up as an independent non-profit, with the AI Security Institute as the template for how it is run.

The money is split unevenly between cash and credits. The government is putting in £100m, roughly $134m, and that is the only cash in the package. OpenAI has pledged £100m of compute and model credits, together with trusted access through its Rosalind Biodefense programme. Anthropic has pledged up to £100m in model credits, trusted access and technical support. Added together, the two companies could contribute as much as £200m, and up to £300m with the state's share, though the ceiling only matters if the lab actually draws it all down.

“will be a major new global institution, bringing together world-leading scientific expertise to protect people from emerging biological threats and ensure Britain leads the world in AI safety and security.”

Kanishka Narayan, UK AI minister, as quoted by Engadget · engadget.com ↗

That last point is the caveat TECHi raises: company support comes in kind, not as money in the bank, so its real worth depends on how much work the lab does with it. TECHi also notes that it corrected its own headline after first overstating Anthropic's pledge, which the official notice words as an upper limit. Engadget's write-up contains an apparent slip too, listing a Google DeepSeek among the backers. The official notice is clear that Google DeepMind is a research partner rather than a funder, and that is the version used here.

Google DeepMind will contribute biosecurity specialists and is planned to give the lab trusted access to Gemini and its science models. Basecamp Research, a UK company building AI models for biology, joins as the other research partner. Around the lab, the initiative ties together the UK Health Security Agency, the Animal and Plant Health Agency and the defence science laboratory Dstl, alongside the life sciences sector. The medicines regulator, the MHRA, will work with the lab on preparing for health emergencies and on how AI-designed medicines should be regulated.

The package is also meant to stitch government science to the private labs. In practice that means the lab will sit between public health and animal-health agencies, a defence research body, the life sciences industry and the companies whose models it is meant to study, so that threat detection and countermeasure work can share tools and expertise rather than start from scratch in each organisation.

The stated starting priorities are spotting emerging biological threats earlier and getting vaccines, treatments and other countermeasures out faster. The government's framing is two-sided: AI opens large opportunities for science, but increasingly capable systems also create new biological risks and could make it easier to cause harm. It wants the lab to have enough independence to move at the pace of a frontier AI and biology company, and says it intends to fund it from public and philanthropic sources over time.

Engadget links the announcement to a recent claim from a California AI lab that it had used AI to design a virus and given it to a human patient; the virus was built to target antibiotic-resistant bacteria. Minister Kanishka Narayan, who announced the lab, calls it a major new global institution, and the government's stated ambition is for Britain to be a leader in this field. The reporting stresses the two-sided argument the announcement makes: the same technology that could speed up detection and cures is also the reason a dedicated body is thought necessary, and the lab is meant to work on both halves of that problem at once.

Details are still to come. A scientific advisory committee drawing on academia, industry and the third sector will be set out at a later date, and the outlets give no timetable for when the lab will start work. The one firm commitment so far is the £100m of public money, with philanthropic funding described only as an intention for later. Because the companies' contributions are credits and access rather than cheques, how much they are ultimately worth will be decided by how heavily the lab uses them.